Cefepime microbiologic profile and update

被引:20
作者
Kessler, RE [1 ]
机构
[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
关键词
cefepime; microbiologic profile; fourth generation cephalosporin;
D O I
10.1097/00006454-200103000-00031
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The evolution of the cephalosporin class of antibiotics through modifications of the basic cephem structure has resulted in a new generation with improved antibacterial activity. Cefepime is a prototypic agent of this new class of fourth generation cephalosporins. Objective. To review the microbiologic profile of cefepime. Results. Cefepime, which is a zwitterion, has a net neutral charge that allows it to penetrate the outer membrane of Gram-negative bacteria faster than third generation cephalosporins. It is more stable against beta-lactamases because of the lower affinity of the enzymes for cefepime when compared with third generation cephalosporins. As a result of these structural attributes, cefepime has in vitro activity against pathogens that are prevalent in pediatric infections. This agent offers the advantage of Gram-positive coverage similar to that of cefotaxime and ceftriaxone, as well as good activity against Pseudomonas aeruginosa and many enteric bacilli that are resistant to third generation cephalosporins, including clinical isolates of Enterobacter spp. and Citrobacter freundii. Conclusions. Based on its spectrum of activity cefepime is an option for the treatment of pediatric infections caused by susceptible pathogens.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 45 条
[1]   Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia [J].
Ambrose, PG ;
Richerson, MA ;
Stanton, ME ;
Bui, K ;
Nicolau, DP ;
Nightingale, CH ;
Quintiliani, R .
INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1999, 8 (05) :245-251
[2]   CEFEPIME - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
BARRADELL, LB ;
BRYSON, HM .
DRUGS, 1994, 47 (03) :471-505
[3]   CEFEPIME [J].
CUNHA, BA ;
GILL, MV .
MEDICAL CLINICS OF NORTH AMERICA, 1995, 79 (04) :721-732
[4]  
Fontana R, 1996, J CHEMOTHERAPY, V8, P23
[5]  
Fung-Tomc Joan C., 1997, Clinical Microbiology Newsletter, V19, P129, DOI 10.1016/S0196-4399(97)82485-3
[6]   FREQUENCY OF INVITRO RESISTANCE OF PSEUDOMONAS-AERUGINOSA TO CEFEPIME, CEFTAZIDIME, AND CEFOTAXIME [J].
FUNGTOMC, J ;
HUCZKO, E ;
PEARCE, M ;
KESSLER, RE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1443-1445
[7]  
GEFFROY CE, 1997, 3 INT S FEBR NEUTR B, P30
[8]  
Gould I. M., 1999, Clin Microbiol Infect, V5 Suppl 1, pS1, DOI 10.1111/j.1469-0691.1999.tb00717.x
[9]   Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth-generation cephalosporin [J].
Grossman, RF ;
Campbell, DA ;
Landis, SJ ;
Garber, GE ;
Murray, G ;
Stiver, HG ;
Saginur, R ;
McIvor, RA ;
Laforge, J ;
Rotstein, C ;
Dubois, J ;
Rivard, M ;
Boulerice, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :549-554
[10]  
Hancock REW, 1996, J CHEMOTHERAPY, V8, P31